Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (NCT05496036)
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Who can join: Review the eligibility criteria below.
Location: Penn Medicine — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Penn Medicine — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 662-6389
Email: Lydia.Giles@pennmedicine.upenn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Merkel Cell Carcinoma
- Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma — Tampa, Florida
- Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma — Basking Ridge, New Jersey
- Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies — Phoenix, Arizona
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma — Tampa, Florida
- Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns — San Francisco, California
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 — Madison, Wisconsin
Explore by condition: All Merkel Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.